A new postdoctoral fellow position at the intersection of drug resistance, metastasis and drug discovery is available at The Sahin Lab at MUSC Hollings Cancer Center

Published by sahinozgur on

Related Posts

Announcement

The National Cancer Institute has awarded Dr. Sahin’s startup, LoxiGen, Inc., a three-year Fast-track Small Business Technology Transfer (STTR) grant to develop therapy for drug-resistant TNBC in collaboration with scientist at MUSC and USC

Our LOXi project featured in the Cancer Letter! Here is the press release: https://cancerletter.com/drugs-and-targets/20230630_8c/

Announcement

Ozge has been awarded the highly prestigious Scholar-in-Training Award by the AACR

Ozge Saatci received the Scholar-in-Training award to attend the American Association for Cancer Research conference and present her research. Here is the press release: https://hollingscancercenter.musc.edu/news/archive/2023/04/24/hollings-team-ids-protein-that-helps-cancer-cells-in-cell-division-process

Announcement

Our new paper is published in Cell Death & Differentiation

Our latest article has been published in Cell Death & Differentiation. The study focuses on the molecular mechanism of Transforming Acidic Coiled-Coil Containing Protein 3 (TACC3) in highly aggressive breast tumors with Centrosome amplification (CA). Read more…